300147.SHE Xiangxue Pharmaceutical
- Market cap
- CNY 2.88B
- P/E
- -
- P/B
- 8.26x
- ROE
- -
- Dividend yield
- 0.20%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300147.SHE undervalued?
Graham numberThe Graham number of Xiangxue Pharmaceutical cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xiangxue Pharmaceutical fundamental analysis
No fundamental analysis for Xiangxue Pharmaceutical yet.
Xiangxue Pharmaceutical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co.,Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, asia diet sarsae, asia juice soda, asia soymilk, coconut juice, and fruit enzyme; and a…
Full company profileXiangxue Pharmaceutical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Xiangxue Pharmaceutical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.86B | 2.19B | 2.50B | 2.79B | 3.07B | 2.97B | 2.19B | 2.30B | 1.86B | 1.60B | 1.42B |
| Gross Profit | 585M | 632M | 911M | 880M | 979M | 741M | 533M | 743M | 408M | 436M | 451M |
| Operating Income | 60.0M | 106M | 126M | 113M | 229M | -589M | -464M | -333M | -785M | -76.6M | 46.0M |
| EBITDA | 210M | 157M | 370M | 305M | 447M | 125M | 60.3M | 282M | -15.7M | -858M | -255M |
| Net Income | 66.0M | 65.9M | 56.4M | 76.5M | 98.4M | -688M | -530M | -389M | -859M | -1.39B | -557M |
| EPS | 0.10 | 0.10 | 0.09 | 0.12 | 0.15 | -1.05 | -0.80 | -0.59 | -1.30 | -2.11 | -0.84 |
| Balance Sheet | |||||||||||
| Total Assets | 7.99B | 9.44B | 8.63B | 8.46B | 9.78B | 11.4B | 9.35B | 8.28B | 7.50B | 6.75B | 6.63B |
| Total Liabilities | 4.30B | 5.56B | 4.61B | 4.35B | 5.53B | 7.62B | 6.53B | 5.97B | 6.06B | 6.70B | 7.00B |
| Shareholders' Equity | 3.40B | 3.46B | 3.43B | 3.49B | 3.62B | 2.95B | 2.41B | 1.92B | 1.05B | -360M | -773M |
| Cash & Short-term Investments | 862M | 1.41B | 673M | 524M | 624M | 262M | 167M | 149M | 145M | 255M | 165M |
| Total Debt | 2.35B | 3.47B | 3.62B | 2.68B | 3.96B | 3.45B | 2.46B | 2.43B | 1.96B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 198M | 110M | 91.2M | 83.0M | 257M | 258M | 227M | 263M | 18.2M | 140M | - |
| Capital Expenditure | 1.97B | 778M | 495M | 661M | 707M | 563M | 367M | 56.0M | 35.2M | 21.5M | 24.9M |
| Free Cash Flow | -1.77B | -668M | -404M | -578M | -450M | -305M | -140M | 207M | -17.1M | 118M | -104M |
| Ratios | |||||||||||
| ROE | 1.9% | 1.9% | 1.6% | 2.2% | 2.7% | -23.4% | -22.0% | -20.2% | -81.4% | - | - |
| ROA | 0.8% | 0.7% | 0.7% | 0.9% | 1.0% | -6.0% | -5.7% | -4.7% | -11.4% | -20.6% | -8.4% |
| Net Profit Margin | 3.5% | 3.0% | 2.3% | 2.7% | 3.2% | -23.2% | -24.2% | -16.9% | -46.2% | -87.3% | -39.3% |
| Debt to Equity | 0.69x | 1.00x | 1.06x | 0.77x | 1.10x | 1.17x | 1.02x | 1.26x | 1.85x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Xiangxue Pharmaceutical dividends
- Dividend yield
- 0.20%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 23, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 5.84M | 0.01 | - |
| 2024 | CNY 50.5M | 0.08 | - |
| 2023 | CNY 141M | 0.21 | - |
| 2022 | CNY 176M | 0.27 | - |
| 2021 | CNY 217M | 0.33 | - |
| 2020 | CNY 31.3M | 0.05 | 31.8% |
| 2019 | CNY 21.3M | 0.03 | 27.8% |
| 2018 | CNY 207M | 0.33 | 367.4% |
| 2017 | CNY 172M | 0.26 | 261.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on Jul 14, 2014.
Who owns Xiangxue Pharmaceutical
- Insiders 32.03%
- Institutions 0.00%
- Public & others 67.97%
- Shares outstanding 661M
- Free float 496M
Xiangxue Pharmaceutical company profile
- Company name
- Xiangxue Pharmaceutical
- Ticker
- 300147.SHE
- ISIN
- CNE100000Y92
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 15, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,662
- Fiscal year end
- December
- Address
- No. 2 Jinfengyuan Road, Guangzhou, China, 510663
- Phone
- 86 20 2221 1555
- Website
- xphcn.com
About Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co.,Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, asia diet sarsae, asia juice soda, asia soymilk, coconut juice, and fruit enzyme; and antiviral oral liquids under the Xiangxue brand name. It also provides medical devices, which includes disposable stereoscopic fixation system for brain; medical orthopedic and cosmetic adhesives; medical tumor serosa sealing adhesives; medical anastomotic adhesives; medical aural and encephalic adhesives; medical obturation adhesives; medical adhesives; and endoscopic trocar. Xiangxue Pharmaceutical Co.,Ltd. was founded in 1986 and is based in Guangzhou, China.
Xiangxue Pharmaceutical management
7- Mr. Yonghui WangChairman & GM · born 1962
- Mr. Feng LuFinancial Director · born 1973
- Mr. Lun ZengVice President · born 1969
- Mr. Guanghua TanGeneral Manager of Marketing Center · born 1978
- Ms. Zhiying KangGM of Technology R&D · born 1977
- Mr. Junliang ZhongGeneral Manager of Supply Chain · born 1972
- Runxi LiuAccounting Supervisor